Sign In
24 Jul 2013 13:39
Cyprotex PLC
("Cyprotex" or the "Company")
Appointment of Non-Executive Director
Cyprotex PLC (AIM:CRX), a specialist ADME-Tox Contract Research Organisation is pleased to announce that Christopher Mills will join the Board of Cyprotex as Non-Executive Director with immediate effect.
Christopher Mills is a Director and investment manager of Oryx International Growth Fund Limited which currently has a stake of 27.3% in Cyprotex. He brings a wealth of experience to the Board, having been a Director for the last four years of Celsis Group Limited, which was the owner of In Vitro Technologies, the leading supplier of cryopreserved human liver cells to the ADME-Tox testing industry including Cyprotex, until it was sold by Celsis in June 2013. Mr Mills was also a Director of Bionostics Holdings Limited, an analytical life science manufacturer of in vitro diagnostic quality controls, for five years until its sale in July 2013, and is currently a Director of medical materials supplier Orthoproducts Limited.
Dr Anthony Baxter, Chief Executive Officer, commented " It is a great honour to have someone of Christopher Mills calibre and experience joining the Cyprotex Board. We look forward to working with Christopher to further enhance the financial performance of the business"
Christopher Harwood Bernard Mills, aged 60, currently holds or has held the following directorships and partnerships in the last five years:
Current UK Directorships/LLP memberships | Past UK Directorships/LLP memberships
|
Harwood Holdco Limited | Aerte Group PLC |
Harwood Capital LLP | JO Hambro Capital Management Limited |
North Atlantic Smaller Companies Investment Trust PLC | JO Hambro Capital Management (America) Limited |
Second London American Trust PLC (In Members' Voluntary Liquidation) | London Trust Productions Limited |
Consolidated Venture Finance Limited | Autotag Fulfilment Limited |
Growth Financial Services Limited | Izodia PLC |
Cross Border Limited | Prime Focus London PLC |
Cross-Border Publishing (London) Limited | Castle Support Services PLC |
Baltimore Capital PLC (in members' voluntary liquidation) | Orthoplastics Limited |
Forefront Group Limited | Dowding and Mills Public Limited Company |
Mount Street Properties Limited | Inspired Gaming Group Limited |
Catalyst Media Group Plc | Sirvis IT Limited |
Catalyst Media Holdings Limited | Darby Glass Limited |
Darby Group Limited (proposal to strike off) | Sirvis IT Holdings Limited |
Bionostics Holdings Limited | Johcm Alternative Investments LLP |
Alternateport Limited | Deepenhart Limited |
Satellite Information Services (Holdings) Limited | American Opportunity Trust PLC |
Bionostics Limited | Lot Limited |
62 Pont Street (Freehold) Limited | Boostcareer Limited |
M J Gleeson Group Public Limited Company | GEI Group Limited |
Valiant Sports Holdings Limited | Jarvis Porter Group PLC |
Orthoproducts Limited | Jarvis Porter (Property Holdings) Limited |
Essenden Public Limited Company | Further Signed Limited |
Nationwide Accident Repair Services Plc | Hampton Trust PLC |
Nastor Investments Limited | Mount Street Properties Limited |
Celsis International Limited | Hampton Land & Estates Limited |
Alba Investment Properties Limited | Crucible Equity Limited |
Alba Investment Properties Holdings Limited | Crucible Acquisitions Limited |
Alba Investment Properties Intermediate Holdings Limited | Albany Capital PLC |
W.G. Mitchell (Charlotte Square) Limited | Densa Ltd |
W.G. Mitchell (George Street) Limited | Ferraris Development and Engineering Company |
W.G. Mitchell (Fifteen) Limited | Ferraris Healthcare Limited |
W.G. Mitchell (Seven) Limited | Ferraris Instruments Limited |
W.G. Mitchell Enterprises Limited | Reynolds Medical Group Limited |
W.G. Mitchell (2005) Limited | RGS(5) Limited |
Celsis Group Limited | H.Townsend & Sons (Builders) Limited |
AssetCo Plc | Highrix Limited |
Baltimore Technologies (Holdings) Limited |
Toftplan Properties Limited |
Baltimore Technologies (UK) Limited | |
SINAV Limited | |
Harwood Capital Management Limited | |
Academic Research Limited | |
Merchant Properties General Partner Limited | |
Merchant Properties Nominees Limited | |
Merchant Properties Two General Partner Limited | |
Merchant Properties Two Nominee 1 Limited | |
Merchant Properties Two Nominee 2 Limited | |
Harwood Real Estate Limited | |
GTL Resources Limited | |
GTL Resources Overseas Investments Limited | |
Bioquell Plc | |
Harwood Capital Nominees Limited | |
Kelvinhaugh Student Accommodation | |
Team Rock Limited | |
Stratifer Limited |
Christopher Mills has been a Non-Executive Director to the following companies which have been placed into liquidation or receivership/administration:
All creditors paid in full
PNC Telecon PLC (renamed Tricor PLC) | In administration 23.06.03. Discharged 15.01.04. Company now active. |
Nationwide Security Group Limited | Receivers appointed 16.02.00. They realised sufficient assets to repay all creditors and make a small distribution. |
Second London American Trust PLC | In members voluntary liquidation since 15.08.06 |
Baltimore Capital Plc | In members voluntary liquidation |
Deepenhart Ltd | Company dissolved 18.08.10 |
American Distributions Plc | Company dissolved 17.06.05 |
Jubilee Investment Trust | In members voluntary liquidation since 01.02.07 |
J O Hambro Conning Grimston Limited | Members voluntary liquidation 31.05.01 Dissolved 21.03.05 |
Companies that went into liquidation with creditors paid in full other than the pension funds
Jarvis Porter Group PLC | Dissolved 28.11.08 |
United Industries plc | In administration 05.04.06. Dissolved 13.05.08 |
Companies that went into administration and creditors lost money as a result of liquidation
Versatile Group Limited and its subsidiaries Versatile Projects Limted and Castle Finance Limited | Administrative receiver appointed 28.08.98 by Bank of Scotland who had charges and cross guarantees supporting a debt of £2.4 million. In addition, the Group had estimated deficiencies as regards creditors of £0.6 million and total estimated deficiencies in excess of £0.7 million. Versatile Group Limited was struck off the register on 15.05.01 |
There are no other details to be disclosed pursuant to Rule 17 or to Schedule 2 paragraph (g) of the AIM Rules for Companies.
For further information:
Cyprotex PLC | Tel: +44 (0) 1625 505 100 |
Dr Anthony Baxter, Chief Executive Officer John Dootson, Chief Financial Officer Mark Warburton, Chief Operating Officer and Legal Counsel | ir@cyprotex.com www.cyprotex.com |
N+1 Singer (Nomad and broker to Cyprotex) | Tel: +44 (0)20 7496 3000 |
Shaun Dobson Jenny Wyllie | shaun.dobson@n1singer.comjenny.wyllie@n1singer.comwww.n1singer.com |
FTI Consulting | Tel: +44 (0) 20 7831 3113 |
Simon Conway Mo Noonan | cyprotex@fticonsulting.com www.fticonsulting.com |
About Cyprotex PLC
Cyprotex is based in Macclesfield, near Manchester in the UK, and Watertown, MA in the US and is listed on the AIM market of the London Stock Exchange (CRX). The company was established in 1999 and works with more than 700 partners. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010 and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services, extending from early drug discovery through to IND submission. The company's core capabilities include high quality in vitro ADME screening services, mechanistic toxicology and high content toxicology screening services including CellCiphr® Premier and eCiphrCardio, and predictive modelling using PBPK and QSAR techniques including Cloe® PK for in vivo PK prediction. For more information, see www.cyprotex.com.
Follow the stocks
